Scholar Rock Holding Corporation is a biopharmaceutical company that develops treatments for serious diseases involving protein growth factors. Their lead candidate Apitegromab has completed Phase 3 clinical trials for spinal muscular atrophy while SRK-181 is in Phase 1 for cancers resistant to anti-PD-1 therapies. Additionally, the company has a collaboration agreement with Gilead Sciences to develop inhibitors of transforming growth factor beta activation for fibrotic diseases.